Global Ewing’s Sarcoma Pipeline Insights 2021: Pipeline Product Profiles, Therapeutic Assessment, Pipeline Assessment, Inactive Drugs Assessment, Unmet Needs – ResearchAndMarkets.com

Global Ewing’s Sarcoma Pipeline Insights 2021: Pipeline Product Profiles, Therapeutic Assessment, Pipeline Assessment, Inactive Drugs Assessment, Unmet Needs – ResearchAndMarkets.com




Global Ewing’s Sarcoma Pipeline Insights 2021: Pipeline Product Profiles, Therapeutic Assessment, Pipeline Assessment, Inactive Drugs Assessment, Unmet Needs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ewing’s Sarcoma – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Ewing’s Sarcoma – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Ewing’s Sarcoma pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ewing’s Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Ewing’s Sarcoma.

Ewing’s Sarcoma Emerging Drugs Chapters

This segment of the Ewing’s Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ewing’s Sarcoma Emerging Drugs

Vigil immunotherapy: Gradalis, Inc.

Phase III clinical trials are being conducted by gradalis, Inc. for Intradermal autologous Vigil immunotherapy in combination with irinotecan and temozolomide in subjects with metastatic Ewing’s sarcoma Family of Tumors (ESFT).

Eribulin mesylate: Eisai, Inc.

Eribulin Mesylate is the mesylate salt of a synthetic analogue of halichondrin B, a substance with antineoplastic activity. Eribulin mesylate clinical trials are going on in phase II stage of development by eisai, Inc for Ewing sarcoma.

Ewing’s Sarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Ewing’s Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ewing’s Sarcoma

There are approx. 10+ key companies which are developing the therapies for Ewing’s Sarcoma. The companies which have their Ewing’s Sarcoma drug candidates in the most advanced stage, i.e. phase III include, Gradalis, Inc.

Phases

This report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Ewing’s Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Subcutaneous
  • Intravenous
  • Intramuscular
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Bispecific Antibody
  • Peptides
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ewing’s Sarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ewing’s Sarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ewing’s Sarcoma drugs.

Ewing’s Sarcoma Report Insights

  • Ewing’s Sarcoma Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Ewing’s Sarcoma Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Ewing’s Sarcoma drugs?
  • How many Ewing’s Sarcoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ewing’s Sarcoma?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ewing’s Sarcoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Ewing’s Sarcoma and their status?
  • What are the key designations that have been granted to the emerging drugs?

Companies Mentioned

  • Gradalis, Inc.
  • Eisai Inc.
  • Aadi, LLC
  • Salarius Pharmaceuticals
  • Oncternal Therapeutics, Inc
  • Nanovalent pharmaceuticals
  • Gibson Oncology
  • Oncoheroes Biosciences
  • Edison Oncology

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/r92xen

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900